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aspects. The purpose of the study was to evaluate the
QOL in 223 patients (age 18–70 years old) with SLE and
to estimate the cost-effectiveness of the optimization of
treatment (OT). METHODS: After appropriate investi-
gation, patients received the optimized treatment with
adequate carbamazepine or valproate monotherapy. (Pre-
viously 139 patients were on inadequate treatment with
low-dose polytherapy, 84 patients were untreated). 
Frequency, severity (NHS3 scale, M.F. Donoghue et al.,
1996) of seizures and QOL (QOLIE-31 scale, J. Cramer
1998) were analyzed as effectiveness parameters before
and 1 year after the OT. RESULTS: After OT complete
control of seizures (CCS) was achieved in 122 patients
(54.7%). Before OT the signiﬁcant (p < 0,01) negative
correlation was found between the QOLIE-31 overall
score (OS) and the duration of disease (r = -0,34), sever-
ity (r = -0,33) and frequency of seizure. In patients with
CCS the improvement of QOL was the most signiﬁcant.
QOL in patients with remaining rare seizures was signiﬁ-
cantly lower than in CCS group. Clinical efﬁcacy/tolera-
bility, QOL improvement, cost-effectiveness parameters
were similar on carbamazepine or valproate, that sup-
ports the use of valproate as adequate ﬁrst-line drugs in
patients with SLE. In patients with initial inadequate
polytherapy the cost of 100% remission (CCS) after OT
(valproate monotherapy) was 125 USD per year. CON-
CLUSIONS: Duration of epilepsy, severity, frequency of
seizures have the main impact on QOL. Complete control
of seizures is essential for improvement of QOL. Results
of pharmacoeconomical analysis support the necessity of
OT in epilepsy patients.
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OBJECTIVES: Epilepsy has a signiﬁcant impact on the
patient, with higher frequency of seizures being associ-
ated with lower quality of life. The association between
utility and epilepsy clinical status is less well deﬁned. In
this analysis, we present utility values that were collected
during a prospective study of patients with intract-
able epilepsy and describe the association between utility
scores and clinical status. METHODS: One hundred
twenty-ﬁve patients with intractable epilepsy were
recruited at a tertiary referral centre in London, UK. At
recruitment, each patient was about to start treatment
with a new adjunctive anti-epileptic drug (AEDs). Pa-
tients were interviewed at baseline, three months and 
six months. At each visit patients completed a semi-
structured interview, the National Hospital seizure 
severity and frequency scale and the EuroQol EQ-5D.
Results are presented for both the EQ-5D tariff and VAS
(visual analogue) scores. Clinical response was deter-
mined as a 50% or greater reduction in baseline median
seizure frequency. RESULTS: At baseline, mean EQ utility
score was 0.850, (VAS = 65.08). Mean values were lower
in patients with higher seizure frequency, with utility
scores of 0.798, 0.902 and 0.934 in patients with >10,
2–9 and £1 seizure per month, respectively. VAS scores
were 62.85, 66.96 and 70.71 for these groups. At 6
months, 20/125 patients had become seizure-free, with a
mean utility value of 0.923 (VAS = 77.63), compared with
0.824 (VAS = 66.56) in patients who did not achieve a
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50% reduction in seizures. The mean utility value of
patients who prematurely discontinued treatment (n = 50)
was 0.846 (VAS = 64.89). CONCLUSIONS: More fre-
quent epilepsy seizures were associated with lower utility
values in this prospective study of patients with active
epilepsy. In addition, patients who became seizure-free on
treatment reported higher utility gains than those who
failed to respond. Better seizure control may result in
utility gains in epilepsy patients.
NEUROLOGICAL DIESEASES/DISORDERS &
PAIN—Healthcare Policy
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OBJECTIVES: Low back pain is a serious problem that
results in lost time from work and reduced quality of life.
The annual cost of low back pain in the United States is
estimated to be billions of dollars. The primary objective
of this study was to characterize the most commonly used
drug therapies for treatment of low back pain in a
managed care organization (MCO). METHODS: We per-
formed a retrospective analysis on enrollment, medical,
and pharmacy claims data from 19 discounted, fee-
for-service, independent practice association model plans
afﬁliated with a large MCO. Commercial members with
a claim for low back pain identiﬁed by appropriate ICD-
9 codes during a speciﬁed 6-month period were included
for analysis. Results were stratiﬁed based on the follow-
ing treatment patterns: new treatment, ongoing treat-
ment, and no treatment. RESULTS: About half of the
96,024 diagnosed patients did not ﬁll a prescription, and
the new and ongoing treatment groups were about evenly
split. Mean age was 42 years, with 46.7% male. About
half of subjects received >1 drug. In both the new and
ongoing groups hydrocodone/acetaminophen was the
most common pain medication for both groups, 
prescribed in 27.7% and 41.2% of cases, respectively.
Naproxen was the second most prescribed drug for newly
treated patients (25.8%) and cyclopbenzaprine (21%) the
second most prescribed drug in the ongoing group. Oxy-
codone/acetaminophen was used in 7.6% of the newly
treated patients and in 13% of the ongoing group. Oxy-
codone was used in 8.1% of the ongoing group, but was
not among the top 20 drugs prescribed in the newly
treated group. CONCLUSIONS: We observed titration in
treatment for pain in the ongoing users who switched to
more potent, long-acting medications to control their low
back pain. The increased utilization of narcotic analgesics
could have signiﬁcant quality of care, productivity, 
disability, and cost implications.
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OBJECTIVE: Compliance with Alzheimer’s Disease (AD)
medication is an important determinant of their effec-
tiveness. This study tests whether differences in com-
pliance were observed with two AD medications that
have different administration schedules (od versus bid).
METHOD: Data for ﬁrst-time users of donepezil and
rivastigmine between October 1, 2000 and March 31,
2002 were extracted from the Quebec Health Insurance
Board database. Two cohorts were identiﬁed: rivastig-
mine and donepezil. Information on sex, age and com-
pliance was gathered at 3, 6, 9 and 12 month following
their ﬁrst prescription. Compliance was measured by
using the total number of days covered by patients’ 
prescriptions within the 3, 6, 9 or 12 month period. 
If patients consumed at least 80% of their medication
they were assumed to be compliant. Statistical difference
at 95% between the proportions in each group was
assessed. RESULTS: A total of 6267 patients (69% of
women) with a mean age of 78.6 in the donepezil cohort
and 773 (48% of women) with a mean age of 77.3 in the
rivastigmine group were identiﬁed. At month 3, no 
statistical difference (CI: -0.82–0.88) in compliance
between donepezil (77.6%) and rivastigmine (74.6%)
was detected. The same conclusion was reached for the
analysis at month 6, 9 and 12. Of note, a large decrease
in the compliance in both groups was observed from
month 3 to month 12. However, the trend is very similar
in both groups. CONCLUSION: No statistically signiﬁ-
cant difference in compliance was observed between
patients on rivastigmine and donepezil. Furthermore, no
difference in the compliance trend (from month 3 to 12)
in both groups was observed. Finally, compliance with
AD medication did not seem to differ depending of the
administration schedules (od versus bid).
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OBJECTIVE: To estimate the incremental pharmacy
PMPM change according to various formulary designs 
for interferon-beta-1a using administrative claims data
METHODS: Cross-sectional sex- and age-speciﬁc disease
prevalence and treatment rates for multiple sclerosis (MS)
patients were measured using integrated medical and
pharmacy claims data from a 508,066-member employer
